CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:New avenues for cancer immunotherapy: Cell-mediated drug delivery systems.
New avenues for cancer immunotherapy: Cell-mediated drug delivery systems.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过去几十年来,随着对癌细胞异质性、增殖能力及其肿瘤微环境认识的不断深入,癌症研究变得日益复杂。尽管传统疗法至今仍是癌症治疗最引人注目的选择,但免疫疗法是一种有前景的方式,可利用天然免疫防御来靶向和杀死癌细胞。细胞介导的药物递送系统(CDDSs)一直是增强癌症免疫疗法疗效和特异性的活跃研究方向。这些系统可针对不同类型的免疫细胞进行定制,从而实现免疫逃逸并在肿瘤微环境中蓄积。通过实现免疫刺激剂、细胞因子、抗体和抗原等治疗药物的靶向递送,CDDSs 改善了部分癌症患者的生存。本综述总结了 CDDSs 的研究现状,重点介绍其基本作用机制、生物学和临床应用。我们还讨论了将 CDDSs 纳入主流癌症免疫疗法的机遇与挑战。
Cancer research has become increasingly complex over the past few decades as knowledge of the heterogeneity of cancer cells, their proliferative ability, and their tumor microenvironments has become available. Although conventional therapies remain the most compelling option for cancer treatment to date, immunotherapy is a promising way to harness natural immune defenses to target and kill cancer cells. Cell-mediated drug delivery systems (CDDSs) have been an active line of research for enhancing the therapeutic efficacy and specificity of cancer immunotherapy.
These systems can be tailored to different types of immune cells, allowing immune evasion and accumulation in the tumor microenvironment. By enabling the targeted delivery of therapeutic agents such as immune stimulants, cytokines, antibodies, and antigens, CDDSs have improved the survival of some patients with cancer. This review summarizes the research status of CDDSs, with a focus on their underlying mechanisms of action, biology, and clinical applications.
We also discuss opportunities and challenges for implementation of CDDSs into mainstream cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。